Sulfadoxine-pyrimethamine plus artesunate — Competitive Intelligence Brief

Sulfadoxine-pyrimethamine plus artesunate (Sulfadoxine-pyrimethamine plus artesunate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate) Infectious Disease Small molecule

Target snapshot

Sulfadoxine-pyrimethamine plus artesunate (Sulfadoxine-pyrimethamine plus artesunate) — London School of Hygiene and Tropical Medicine. This combination drug kills malaria parasites by inhibiting their folate metabolism (sulfadoxine-pyrimethamine) and disrupting their mitochondrial function (artesunate).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sulfadoxine-pyrimethamine plus artesunate TARGET	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)
Artesunate + Mefloquine	Artesunate + Mefloquine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (multiple targets: artemisinin-induced reactive oxygen species; mefloquine-heme polymerase inhibition)
Artesunate/mefloquine (AS/MQ)	Artesunate/mefloquine (AS/MQ)	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification
Artesunate and Pyronaridine	Artesunate and Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Malaria parasite (Plasmodium species) — multiple targets including heme polymerization and oxidative stress pathways
Atovaquone / Proguanil	Atovaquone / Proguanil	Radboud University Medical Center	marketed	Antimalarial combination	Mitochondrial electron transport chain (atovaquone); dihydrofolate reductase (proguanil)
artemisinin/naphthoquine	artemisinin/naphthoquine	Ifakara Health Institute	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and mitochondrial electron transport
Artemether + Lumefantrine	Artemether + Lumefantrine	GlaxoSmithKline	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and heme detoxification pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class